Boston Scientific Corp Declines Amid Market Weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2024
0mins
Should l Buy BSX?
Boston Scientific Corp's stock has declined by 3.00%, hitting a 20-day low amid broader market weakness.
The Nasdaq-100 is up slightly by 0.11%, while the S&P 500 has dipped by 0.06%, indicating a mixed market sentiment that has not favored Boston Scientific.
Despite a bullish outlook from analysts regarding the company's growth potential, the stock's recent performance reflects broader challenges in the market, suggesting investors are cautious.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BSX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BSX
Wall Street analysts forecast BSX stock price to rise
22 Analyst Rating
22 Buy
0 Hold
0 Sell
Strong Buy
Current: 69.960
Low
94.00
Averages
108.14
High
132.00
Current: 69.960
Low
94.00
Averages
108.14
High
132.00
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Boston Scientific Securities Fraud Lawsuit Reminder
- Lawsuit Deadline: Investors must file a lead plaintiff motion by May 4, 2026, for Boston Scientific (BSX) securities purchased between July 23, 2025, and February 3, 2026, highlighting the urgency for investors to seek legal recourse following disappointing performance.
- Disappointing Performance: On February 4, 2026, Boston Scientific reported fourth quarter and full year results that revealed underperformance in U.S. Electrophysiology sales, leading to a 17.6% drop in stock price to $75.50, indicating a significant loss of market confidence in the company's growth prospects.
- False Statement Allegations: The lawsuit alleges that throughout the class period, the company made materially false and misleading statements, failing to disclose unsustainable growth rates and the impact of new competitors, reflecting a serious misjudgment by management regarding market conditions.
- Investor Rights Protection: Investors who purchased Boston Scientific securities during the class period may apply to be lead plaintiff before the deadline, indicating that legal avenues are available for affected investors to seek potential remedies.
See More
Brandon Walker Encourages Boston Scientific Investors to Reach Out
- Legal Investigation Launched: Bragar Eagel & Squire, P.C. is investigating Boston Scientific Corporation to determine if its board breached fiduciary duties, particularly following a class action complaint filed on March 5, 2026, covering the period from July 23, 2025, to February 3, 2026.
- False Statement Allegations: The lawsuit alleges that Boston Scientific made materially false and misleading statements during the class period, failing to disclose that its U.S. Electrophysiology (EP) segment's growth rate was unsustainable and that new competitors were threatening its market share, thus limiting growth potential.
- Market Confidence Eroded: The executives' repeated confidence in the U.S. EP division's growth trajectory is claimed to be misleading, which may have affected investors' positive perceptions of the company's business, operations, and prospects, lacking a reasonable basis.
- Investor Rights Protection: Bragar Eagel & Squire encourages long-term shareholders to contact them for more information regarding these claims, indicating the firm's commitment to protecting investor rights, with no cost for participation in the investigation.
See More
Class Action Lawsuit Filed Against Boston Scientific Corporation
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025, and February 3, 2026, indicating significant legal risks facing the company.
- Lawsuit Context: During the class period, Boston Scientific's management made optimistic statements while concealing the unsustainable growth of its U.S. Electrophysiology segment, leading to investor losses when the company missed net income expectations, highlighting deficiencies in corporate governance and disclosure practices.
- Investor Rights Protection: Investors can join the lawsuit without upfront costs through a contingency fee arrangement, demonstrating Rosen Law Firm's commitment to safeguarding investor rights and providing legal support, thereby enhancing investor confidence in the legal process.
- Firm's Reputation: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its leadership in the industry and strong support capabilities for investors.
See More
Boston Scientific Class Action Lawsuit Announcement
- Class Action Initiation: Boston Scientific faces a class action lawsuit for alleged violations of the Securities Exchange Act during stock transactions from July 23, 2025, to February 3, 2026, with investors having until May 4, 2026, to seek lead plaintiff status, highlighting significant legal risks for the company.
- Declining Financial Performance: On February 4, 2026, Boston Scientific reported Q4 2025 earnings with a net income of $672 million and EPS of $0.45, which, despite year-over-year growth, fell short of the company's guidance range of $0.48 to $0.52, resulting in a stock price drop of over 17%, reflecting market concerns about its growth outlook.
- Increased Market Competition: The lawsuit alleges that Boston Scientific failed to disclose new competitors in the electrophysiology market, leading to a decline in its market share and limiting growth potential, which could negatively impact investor confidence.
- Legal Representation Process: Robbins Geller Rudman & Dowd LLP, as the lead law firm, emphasizes that any investor who purchased Boston Scientific stock during the class period can apply to be the lead plaintiff, indicating the potential financial liabilities and the importance of protecting investor rights in the ongoing legal proceedings.
See More
Emerging Consolidation Wave in U.S. Markets
- Resurgence of M&A Activity: Over the six months ending March 2026, U.S. merger activity remained robust, with monthly deal counts consistently between 1,000 and 1,300, indicating strong market demand for consolidation despite volatility and macro uncertainty.
- Sector Concentration Trend: Frequent mergers in consumer health, semiconductors, medical devices, and media entertainment suggest that companies in these sectors are consolidating to enhance scale and competitiveness in response to rising costs and technological pressures.
- Clear Strategic Motivations: In consumer products, companies merge brand portfolios to strengthen negotiating power with retailers; semiconductor firms seek scale due to rising R&D costs; and medical technology companies acquire innovative platforms to accelerate product development.
- Emerging Investment Opportunities: As the consolidation wave accelerates, investors should focus on identifying companies that may become acquisition targets, as recognizing integration opportunities within industries could yield significant returns.
See More
Boston Scientific Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Boston Scientific (NYSE:BSX), encouraging those who purchased shares during the class period from July 23, 2025, to February 3, 2026, to contact the firm regarding potential lead plaintiff appointment, indicating significant legal risks for the company.
- False Statements Allegations: The complaint alleges that Boston Scientific's management made overwhelmingly positive statements while concealing the true state of its U.S. EP segment's growth, which has severely undermined investor confidence and negatively impacted shareholder interests.
- Disappointing Performance: On February 4, 2026, Boston Scientific reported fourth quarter and full year results that fell short of expectations, particularly in U.S. EP sales, leading to guidance for fiscal 2026 that was well below market expectations, exacerbating investor anxiety about the company's future.
- Stock Price Plunge: Following the disappointing earnings announcement, Boston Scientific's stock price plummeted from $91.62 per share on February 3, 2026, to $75.50 per share on February 4, 2026, marking a dramatic 17.6% decline in just one day, reflecting the market's pessimism about the company's outlook.
See More
Boston Scientific Securities Fraud Lawsuit Reminder
- Lawsuit Deadline: Investors must file a lead plaintiff motion by May 4, 2026, for Boston Scientific (BSX) securities purchased between July 23, 2025, and February 3, 2026, highlighting the urgency for investors to seek legal recourse following disappointing performance.
- Disappointing Performance: On February 4, 2026, Boston Scientific reported fourth quarter and full year results that revealed underperformance in U.S. Electrophysiology sales, leading to a 17.6% drop in stock price to $75.50, indicating a significant loss of market confidence in the company's growth prospects.
- False Statement Allegations: The lawsuit alleges that throughout the class period, the company made materially false and misleading statements, failing to disclose unsustainable growth rates and the impact of new competitors, reflecting a serious misjudgment by management regarding market conditions.
- Investor Rights Protection: Investors who purchased Boston Scientific securities during the class period may apply to be lead plaintiff before the deadline, indicating that legal avenues are available for affected investors to seek potential remedies.
See More
Brandon Walker Encourages Boston Scientific Investors to Reach Out
- Legal Investigation Launched: Bragar Eagel & Squire, P.C. is investigating Boston Scientific Corporation to determine if its board breached fiduciary duties, particularly following a class action complaint filed on March 5, 2026, covering the period from July 23, 2025, to February 3, 2026.
- False Statement Allegations: The lawsuit alleges that Boston Scientific made materially false and misleading statements during the class period, failing to disclose that its U.S. Electrophysiology (EP) segment's growth rate was unsustainable and that new competitors were threatening its market share, thus limiting growth potential.
- Market Confidence Eroded: The executives' repeated confidence in the U.S. EP division's growth trajectory is claimed to be misleading, which may have affected investors' positive perceptions of the company's business, operations, and prospects, lacking a reasonable basis.
- Investor Rights Protection: Bragar Eagel & Squire encourages long-term shareholders to contact them for more information regarding these claims, indicating the firm's commitment to protecting investor rights, with no cost for participation in the investigation.
See More
Class Action Lawsuit Filed Against Boston Scientific Corporation
- Class Action Initiation: Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased Boston Scientific Corporation (NYSE: BSX) common stock between July 23, 2025, and February 3, 2026, indicating significant legal risks facing the company.
- Lawsuit Context: During the class period, Boston Scientific's management made optimistic statements while concealing the unsustainable growth of its U.S. Electrophysiology segment, leading to investor losses when the company missed net income expectations, highlighting deficiencies in corporate governance and disclosure practices.
- Investor Rights Protection: Investors can join the lawsuit without upfront costs through a contingency fee arrangement, demonstrating Rosen Law Firm's commitment to safeguarding investor rights and providing legal support, thereby enhancing investor confidence in the legal process.
- Firm's Reputation: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its leadership in the industry and strong support capabilities for investors.
See More
Boston Scientific Class Action Lawsuit Announcement
- Class Action Initiation: Boston Scientific faces a class action lawsuit for alleged violations of the Securities Exchange Act during stock transactions from July 23, 2025, to February 3, 2026, with investors having until May 4, 2026, to seek lead plaintiff status, highlighting significant legal risks for the company.
- Declining Financial Performance: On February 4, 2026, Boston Scientific reported Q4 2025 earnings with a net income of $672 million and EPS of $0.45, which, despite year-over-year growth, fell short of the company's guidance range of $0.48 to $0.52, resulting in a stock price drop of over 17%, reflecting market concerns about its growth outlook.
- Increased Market Competition: The lawsuit alleges that Boston Scientific failed to disclose new competitors in the electrophysiology market, leading to a decline in its market share and limiting growth potential, which could negatively impact investor confidence.
- Legal Representation Process: Robbins Geller Rudman & Dowd LLP, as the lead law firm, emphasizes that any investor who purchased Boston Scientific stock during the class period can apply to be the lead plaintiff, indicating the potential financial liabilities and the importance of protecting investor rights in the ongoing legal proceedings.
See More
Emerging Consolidation Wave in U.S. Markets
- Resurgence of M&A Activity: Over the six months ending March 2026, U.S. merger activity remained robust, with monthly deal counts consistently between 1,000 and 1,300, indicating strong market demand for consolidation despite volatility and macro uncertainty.
- Sector Concentration Trend: Frequent mergers in consumer health, semiconductors, medical devices, and media entertainment suggest that companies in these sectors are consolidating to enhance scale and competitiveness in response to rising costs and technological pressures.
- Clear Strategic Motivations: In consumer products, companies merge brand portfolios to strengthen negotiating power with retailers; semiconductor firms seek scale due to rising R&D costs; and medical technology companies acquire innovative platforms to accelerate product development.
- Emerging Investment Opportunities: As the consolidation wave accelerates, investors should focus on identifying companies that may become acquisition targets, as recognizing integration opportunities within industries could yield significant returns.
See More
Boston Scientific Shareholder Notice Issued
- Shareholder Notice: The Gross Law Firm has issued a notice to shareholders of Boston Scientific (NYSE:BSX), encouraging those who purchased shares during the class period from July 23, 2025, to February 3, 2026, to contact the firm regarding potential lead plaintiff appointment, indicating significant legal risks for the company.
- False Statements Allegations: The complaint alleges that Boston Scientific's management made overwhelmingly positive statements while concealing the true state of its U.S. EP segment's growth, which has severely undermined investor confidence and negatively impacted shareholder interests.
- Disappointing Performance: On February 4, 2026, Boston Scientific reported fourth quarter and full year results that fell short of expectations, particularly in U.S. EP sales, leading to guidance for fiscal 2026 that was well below market expectations, exacerbating investor anxiety about the company's future.
- Stock Price Plunge: Following the disappointing earnings announcement, Boston Scientific's stock price plummeted from $91.62 per share on February 3, 2026, to $75.50 per share on February 4, 2026, marking a dramatic 17.6% decline in just one day, reflecting the market's pessimism about the company's outlook.
See More
